- Home
- RCMT vs TLSI Comparison
RCMT vs TLSI Comparison
Compare RCMT & TLSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RCMT
- TLSI
- Stock Information
- Founded
- RCMT 1971
- TLSI 2010
- Country
- RCMT United States
- TLSI United States
- Employees
- RCMT N/A
- TLSI N/A
- Industry
- RCMT Professional Services
- TLSI Medical Specialities
- Sector
- RCMT Consumer Discretionary
- TLSI Health Care
- Exchange
- RCMT Nasdaq
- TLSI Nasdaq
- Market Cap
- RCMT 165.8M
- TLSI 158.0M
- IPO Year
- RCMT N/A
- TLSI N/A
- Fundamental
- Price
- RCMT $18.97
- TLSI $5.77
- Analyst Decision
- RCMT Strong Buy
- TLSI Strong Buy
- Analyst Count
- RCMT 2
- TLSI 6
- Target Price
- RCMT $37.00
- TLSI $11.75
- AVG Volume (30 Days)
- RCMT 43.3K
- TLSI 39.3K
- Earning Date
- RCMT 03-12-2025
- TLSI 03-27-2025
- Dividend Yield
- RCMT N/A
- TLSI N/A
- EPS Growth
- RCMT 7.73
- TLSI N/A
- EPS
- RCMT 1.95
- TLSI N/A
- Revenue
- RCMT $272,496,000.00
- TLSI $26,891,000.00
- Revenue This Year
- RCMT $8.33
- TLSI $61.29
- Revenue Next Year
- RCMT $11.22
- TLSI $53.21
- P/E Ratio
- RCMT $9.71
- TLSI N/A
- Revenue Growth
- RCMT 3.84
- TLSI 67.90
- 52 Week Low
- RCMT $17.11
- TLSI $3.50
- 52 Week High
- RCMT $29.23
- TLSI $10.42
- Technical
- Relative Strength Index (RSI)
- RCMT 36.27
- TLSI 68.94
- Support Level
- RCMT $19.67
- TLSI $5.40
- Resistance Level
- RCMT $20.88
- TLSI $5.82
- Average True Range (ATR)
- RCMT 0.55
- TLSI 0.24
- MACD
- RCMT -0.00
- TLSI 0.01
- Stochastic Oscillator
- RCMT 18.72
- TLSI 89.19
About RCMT RCM Technologies Inc.
RCM Technologies Inc is a provider of business and technology solutions designed to enhance and maximize the operational performance of its customers. It operates in three segments: Engineering, which provides a comprehensive portfolio of engineering and design services across three verticals: Energy Services, Process & Industrial, and Aerospace, Life Sciences and Information Technology and Specialty Health Care Services, engaged in providing the staffing of health care professionals, primarily health information management professionals, nurses, paraprofessionals, physicians. The company generates maximum revenue from the Specialty Health Care segment. Geographically, it derives a majority of revenue from the United States and also has a presence in Canada, Puerto Rico, and Serbia.
About TLSI TriSalus Life Sciences Inc.
TriSalus Life Sciences Inc is engaged in the research, development, and sales of innovative drug delivery technology and immune-oncology therapeutics to improve outcomes in difficult-to-treat liver and pancreatic cancer. It is developing and marketing two product lines Pressure Enabled Drug Delivery (PEDD) infusion systems, in use today, and an investigational agent, nelitolimod (SD-101), which shows potential to enhance immune system response in the treatment of hepatocellular cancer, pancreatic cancer and other liver solid tumors. TriNav is the newest therapy delivery device with SmartValve technology for the proprietary PEDD approach.